GLOBAL MULTI-STAGE INVESTOR, WORLD-CLASS NETWORK
Approach
Sixty Degree Capital invests in companies creating meaningful change in their industries, across sectors (software, digital infrastructure, healthcare, biotech) and across stages (as early as Series A, as late as pre-IPO).
Advantage
We have a world-class network, specialized in-house expertise, and relationships with marquee investors. This differentiation enables us to support our portfolio companies and generate exceptional returns for our investors.
Our Portfolio
Blog/News
News
Eclypsium Raises $45M To Lock Down Supply-Chain Security
By pwsbuilder |
Portland, OR – January 28, 2025 (FORBES) Fans of The Big Lebowski know the movie’s narrator introduces the protagonist as “the man for this time and place.” Like Lebowski, Portland, Oregon-based Eclypsium is seizing its role in the moment, landing a $45M Series C round led by Ten Eleven Ventures. With the rise of nation-state-backed infrastructure attacks, interest in…
Read More Sixty Degree Capital Celebrates Final Close of Fund III, Raising $250M for VC Investment in High-Growth Tech Companies
By Sixty Degree Capital |
November 23, 2023 – Sixty Degree Capital is excited to announce the final close of its third venture capital fund, with $250M earmarked for high-growth companies from Series A to pre-IPO stages across enterprise software and healthcare. Fund III is already actively deploying capital to industry-leading ventures including Cato Networks, Docker, NextPoint, Strive Health, Navan,…
Read More T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies
By pwsbuilder |
– Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021 August 02, 2021 08:00 ET| Source: T-knife Therapeutics SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for…
Read More Everside Health Announces $164 Million in Growth Equity Funding from NEA and New Investors
By pwsbuilder |
Existing investors NEA, Oak HC/FT and Alta Partners, and new investors, including Endeavor Catalyst, joined the round Funding will accelerate growth, enhance Everside’s technology stack to facilitate predictive, whole-patient care, and support potential M&A opportunities DENVER, July 25, 2022 /PRNewswire/ — Everside Health, LLC, a leading national direct primary care provider, today announced that it has raised $164 million in growth equity funding. Longstanding investor…
Read More KITE AND ARCELLX ANNOUNCE STRATEGIC COLLABORATION TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA
By pwsbuilder |
— Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing — SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for…
Read More CinCor Pharma to be Acquired by AstraZeneca
By pwsbuilder |
January 09, 2023 02:05 ET| Source: CinCor Pharma IncFollow WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor. Marc de Garidel, Chief Executive Officer at CinCor, said: “We are excited about the…
Read More